Wall Street equity analysts covering MacroGenics Inc. (NASDAQ: MGNX) maintain an average 12-month consensus price target hovering around $6.75 to $7.25 per share. Individual target estimates span from a conservative low of approximately $4.00 up to an optimistic high of $11.00 per share, reflecting the high-risk, high-reward nature typical of clinical-stage biotechnology firms dependent on upcoming pipeline data readouts and oncology drug developments.